Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of metabolic disorders
3.2.1.2 Rising R&D activities for developing novel therapeutics
3.2.1.3 Growing awareness and screening programs
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with treatment
3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Diabetes
5.3 Hypercholesterolemia
5.4 Lysosomal storage diseases
5.4.1 Gaucher’s disease
5.4.2 Metachromatic leukodystrophy
5.4.3 Hurler - Scheie
5.4.4 Sanfilipo A
5.4.5 Other lysosomal storage diseases
5.5 Obesity
5.6 Inherited metabolic disorders
Chapter 6 Market Estimates and Forecast, By Therapy Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Drug therapy
6.3 Enzyme replacement therapy
6.4 Substrate reduction therapy
6.5 Gene therapy
6.6 Small molecule-based therapy
6.7 Cellular transplantation
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By End-User, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie, Inc.
10.2 Actelion Pharmaceuticals Ltd.
10.3 Amgen Inc.
10.4 AstraZeneca plc
10.5 Biocon Ltd.
10.6 BioMarin Pharmaceutical, Inc.
10.7 Boehringer Ingelheim GmbH
10.8 Bristol-Myers Squibb Company
10.9 Cipla, Inc.
10.10 CymaBay Therapeutics, Inc.
10.11 Eli Lilly and Company
10.12 Merck KGaA
10.13 Novo Nordisk A/S
10.14 Sanofi SA
10.15 Shire PLC
